Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06959979 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion pushed from Aug 31, 2026 to Feb 28, 2027v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a concern. This project aims to identify genetic markers of sensitivity to CDK4/6 inhibitors in MB, to improve therapies and overcome resistance.
Trial Details
NCT Number NCT06959979
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborators: University of Rome Tor Vergata, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Università degli Studi di Enna Kore
Conditions
(from sponsor)		 Medulloblastoma, Childhood
Related terms Medulloblastoma
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov